Cargando…
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
New immuno-oncology therapies are improving cancer treatments beyond the former standard of care, as evidenced by the recent and continuing clinical approvals for immunotherapies in a broad range of indications. However, a majority of patients (particularly those with immunologically cold tumors) st...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790338/ https://www.ncbi.nlm.nih.gov/pubmed/31321623 http://dx.doi.org/10.1007/s40259-019-00367-0 |